Biopharma & Life Sciences
HilleVax, Inc. Executive Compensation (FY24)
HLVX · Executive and director compensation, fiscal 2023 to 2024
Chief executive, fiscal 2024 ◇ Robert Hershberg |
Free for 3 days · no card
See how HilleVax, Inc.’s pay stands against its peers
- HilleVax, Inc.'s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
- Peer-group intelligence, custom peer reruns and governance screens
- Every other company we cover, with alerts when they file
No card. Nothing is charged, and the trial ends on its own. After the trial: $499/month, or $5,000/year, about two months free.
Data as of November 20, 2026Latest filing (DEF 14A): April 30, 2025
85 figures on this page, cited to the filing that reported them. See the citations
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Hershberg: $9,697,495 → $6,734,876 (30.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is HilleVax, Inc.'s chief executive and what were they paid?
Robert Hershberg was paid $6,734,876 in total compensation as Chairman, President and Chief Executive Officer for fiscal 2024. Compared with the $9,697,495 reported for fiscal 2023, Hershberg's total was 30.6% lower.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Hershberg Chairman, President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Aditya Kohli Former Chief Business Officer and former Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Hershberg Chairman, President and Chief Executive Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Sean McLoughlin Former Chief Operating Officer Departed during or after this year | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Aditya Kohli Former Chief Business Officer and former Chief Operating Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Shane Maltbie Chief Financial Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Shane Maltbie | Option | ◇ | — | ◇ | 2/7/34 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/33 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/9/32 | |
| Option | ◇ | — | ◇ | 12/5/31 | |
| Sean McLoughlin | Option | — | — | ◇ | January 30, 2034 |
| Robert Hershberg | Option | ◇ | — | ◇ | 2/7/34 |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/33 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Aditya Kohli | Option | — | — | ◇ | February 7, 2034 |
| Option | — | — | ◇ | January 31, 2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Robert Hershberg
Chairman, President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Shane Maltbie
Chief Financial Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2024
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Patrick Heron | ◇ | — | ◇ | — | — | — | ◇ |
Julie Gerberding, M.D., M.P.H | ◇ | — | ◇ | — | — | — | ◇ |
Nanette Cocero, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Shelley Chu, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Jaime Sepulveda, M.D., D.Sc., M.P.H | ◇ | — | ◇ | — | — | — | ◇ |
Jeryl Hilleman | ◇ | — | ◇ | — | — | — | — |
Aditya Kohli, Ph.D, Gary Dubin, M.D and Robert Hershberg, M.D., Ph.D served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
What this page does not include
Everything above is a fact HilleVax, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation ReportBoard and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance ReportRealizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
85 figures on this page, cited to the filing that reported them.
85 cited to the filing
Documents cited
- 0000950170-25-060580EXECUTIVE AND DIRECTOR COMPENSATION · Severance and change in control
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “HilleVax, Inc. executive compensation, FY2023–FY2024.” https://intel.velarion.ai/comp/HLVX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about HilleVax, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}